HENNEMAN JOHN B III 4

What Happened John B. Henneman III, a director of Aprea Therapeutics, was granted a total of 15,690 equity awards on June 16, 2026: 3,135 shares reported at $0.00 and 12,555 shares reported as a derivative award at $0.00. These awards are grants (not open‑market purchases or sales) and have no immediate cash value. Per the filing, the restricted stock units (RSUs) will vest and be settled in common stock on June 16, 2027, subject to Henneman’s continued service and possible acceleration under certain conditions.

Key Details

• Transaction date(s): June 16, 2026; Filing date: June 17, 2026 (filed the next day).
• Price: $0.00 for both the 3,135-share grant and the 12,555-share derivative grant.
• Total shares granted: 15,690 (3,135 + 12,555).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote F1: Confirms these shares are RSUs granted 6/16/2026 and vest/settle 6/16/2027, subject to continued service and possible acceleration.
• Footnote F2: Notes an option vests in full on 6/16/2027, also subject to continued service and possible acceleration (appears related to other equity arrangements).
• Timeliness: Filing appears timely (reported the next business day), no late‑filing flag noted.

Context These awards are compensatory equity grants to a director and do not represent an immediate buy or sell of shares; they will convert to common stock only if/when they vest. Such grants are common for board compensation and are not, by themselves, a direct market signal of insider sentiment. When the RSUs settle, they will increase the number of outstanding shares (potential dilution) unless offset by share repurchases.